Abzena – US Headquarters
6325 Lusk Blvd., San Diego, CA 92121
T: (858) 550-4094
Abzena – UK Headquarters
Babraham Research Campus
Cambridge, UK CB22 3AT
T +44 1223 903498
E: info@abzena.com
LinkedIn: https://www.linkedin.com/company/abzena/
X: @AbzenaGroup
W: Abzena.com
LATEST NEWS
Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND
Abzena Launches Next-Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics & Bioconjugates
Moving medicine forward.
Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need.
Over the past 20 years, Abzena has helped hundreds of customers ranging from emerging biotechs to the top large pharmaceutical firms deliver on their research and development objectives and achieve their regulatory and clinical milestones. With extensive scientific knowledge and technical expertise, our global teams provide customers with comprehensive support that minimizes risks and moves new medicines forward faster- with greater success.
Comprehensive biopharmaceuticals & bioconjugate support:
Antibodies, Antibody Fragments (Fabs), Antibody Drug Conjugates (ADCs), Next generation ADCs and conjugate drugs incorporating novel payloads (peptides, oligonucleotides, immune-modulators), Bispecific Antibodies, Monoclonal Antibodies (mAbs), Radioconjugates, Fusion Proteins, Growth Factors, Recombinant and Conjugate Vaccines, Antibody and ADC Biosimilars.
Services that expedite timelines
Abzena develops and implements fully integrated services and tailored, innovative solutions that are designed to rapidly advance your program to its next value inflexion point.
Solutions for improving development
Our extensive scientific capabilities and proprietary solutions are designed to give your program the best chance of clinical and commercial success.
>EpiScreen®– a robust platform which assesses immunogenicity via flow cytometry and completely avoids radioactive assays, delivering better, more granular candidate selection data.
>Composite Human Antibody™ – a deimmunization platform used for designing safer antibodies which maximizes the full potential of the drug.
>Composite Proteins™ – a deimmunization technology that designs safer therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
>ThioBridge™ – a first generation conjugation technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
>LabZient™ – our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.
The Abzena Approach
We are focused on getting it right from the start. From early discovery through commercial, our experienced scientists work with you side-by-side, functioning seamlessly as part of your team—using real-world insights to bring new ideas to the table and then turning them into action. With quality top of mind, we plan the best route, steering your drug program toward regulatory approval, and getting it to patients.
Connect with us today at info@abzena.com or by visiting Abzena.com to discuss your drug program’s needs with our experts.
Posted Date: 11/16/2023
This record has been viewed 3923 times.